As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa ...

Breast cancer patients (N = 354) receiving chemotherapy were randomly assigned in 1:1 ratio to epoetin alfa (40,000 U qw) or standard of care (SOC). QOL was assessed at baseline and week 12.

CONCLUSION: Epoetin alfa administered to patients with cancer-related anemia for up to 16 weeks resulted in significantly improved QOL, increased hemoglobin levels, and decreased transfusion use.

Demographic and baseline characteristics for the two populations are shown in Table 1. Forty patients were enrolled in the study and were compared with 42 age-matched controls. Within the study ...

Fishbane S, et al. Clin J Am Soc Nephrol. 2018;doi.org/10.2215/CJN.11631017.

Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa. WASHINGTON—Roxadustat is superior to epoetin alfa in raising ...

Epoetin also appears to be a growth factor, promoting thrombopoiesis, as well as a trigger for the activation of platelets. In an elegant study in healthy (normal) human volunteers, ...

At a median follow-up of 21.4 months in the Reblozyl group and 20.3 months in the epoetin alfa group, common grade 3 (severe) or 4 (life-threatening) treatment-emergent side effects that occurred ...

Between 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between 1998 and 2000 ...

Editor's Note: The post by Dennis Cotter below addresses the way in which Medicare should incorporate erythropoiesis-stimulating agents (epoetin) into its composite-rate payment for end-stage ...

There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year.1 Peritoneal dialysis is a home renal ...

This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb⩽12 g dl−1 ...